• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4617544)   Today's Articles (4505)   Subscriber (49399)
For: Ferrari T, Lambertini M, Tartari F, Dika E. Melanoma and eruptive naevi during cetuximab treatment: epidermal growth factor inhibitors and a common concern. Clin Exp Dermatol 2021;46:1584-1586. [PMID: 34080222 DOI: 10.1111/ced.14787] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2021] [Indexed: 11/29/2022]
Number Cited by Other Article(s)
1
Targeting EGFR in melanoma - The sea of possibilities to overcome drug resistance. Biochim Biophys Acta Rev Cancer 2022;1877:188754. [PMID: 35772580 DOI: 10.1016/j.bbcan.2022.188754] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 05/15/2022] [Accepted: 06/23/2022] [Indexed: 12/21/2022]
2
Omori R, Miyagaki T, Miyano K, Hashimoto Y, Kadono T. Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient. J Dermatol 2022;49:e264-e265. [PMID: 35403284 DOI: 10.1111/1346-8138.16393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 03/23/2022] [Accepted: 03/28/2022] [Indexed: 01/07/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA